Brief: Lexicon Announces Completion Of Screening In Phase 2B Progress Study Of Lx9211
22/10/2024 13:43
Oct 22 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O :
* LEXICON ANNOUNCES COMPLETION OF SCREENING IN PHASE 2B
PROGRESS
STUDY OF LX9211 IN DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)
* LEXICON PHARMACEUTICALS INC - TOP-LINE DATA FOR LX9211 NOW
ANTICIPATED IN Q1 2025
Source text for Eikon: ID:nGNX5msSmP
Further company coverage: LXRX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview